Loading phase protocol (acute injury or initial treatment): Dose: 500 mcg to 1 mg per injection Frequency: Once daily Duration: 7 to 10 days Injection site: Subcutaneous, ideally near the area of concern Timing: Morning or evening, consistency matters more than specific time Maintenance phase protocol: Dose: 500 mcg to 1 mg per injection Frequency: 2 to 3 times per week Duration: 4 to 8 weeks total protocol length Cycle recommendation: 2 months on, 2 months off Unlike traditional BPC-157 acetate, which is often administered twice daily due to its shorter half-life, the enhanced stability of the arginate form typically allows for once-daily dosing during the loading phase
Why it was included in the FDA ban While animal studies suggest that DIHEXA may tout these brain benefits (17), the FDA says it has not identified any human exposure data. Meaning: The safety and efficacy of DIHEXA for humans is still up in the air
Connective tissue remodeling Remodeling allows newly formed collagen fibers to organize in a way that supports tendon strength and flexibility
While some studies have shown potential benefits positively affecting certain brain functions, much of the evidence comes from small studies or animal studies
Rivaroxaban 10 mg once daily has been FDA-labeled for thromboprophylaxis after high-risk hospitalization of medical patients and after total hip or knee replacement surgery
